N-(喹啉-5-基)乙酰胺 | 42464-80-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: N-(喹啉-5-基)乙酰胺
• 英文名称: 5-acetylaminoquinoline
• 英文别名: Acetylamino-5-chinolin；5-acetamidoquinoline；N-quinolin-5-yl-acetamide；N-[5]quinolyl-acetamide；N-[5]Chinolyl-acetamid；5-(N-acetylamino)-quinoline；N-(quinolin-5-yl)acetamide；N-quinolin-5-ylacetamide
• CAS: 42464-80-2
• 化学式: C₁₁H₁₀N₂O
• mdl: MFCD00466098
• 分子量: 186.213
• InChiKey: JXDASSXQWMYQGN-UHFFFAOYSA-N

物化性质

• 熔点：
  178 °C
• 沸点：
  430.9±18.0 °C(Predicted)
• 密度：
  1.242±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  N-(喹啉-5-基)乙酰胺 在 溴 作用下， 生成 N-(8-bromo-[5]quinolyl)-acetamide
  参考文献：
  名称：

  Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators

  摘要：

  Pharmacokinctic studies in cynomolgus monkeys with a novel prototype selective androgen receptor modulator revealed trace amounts of an aniline fragment released through hydrolytic metabolism. This aniline fragment was determined to be mutagenic in an Ames assay. subsequent concurrent optimization for target activity and avoidance of mutagenicity led to the identification of a pharmacologically superior clinical candidate without mutagenic potential. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.076
• 作为产物：
  描述：

  喹啉 在 盐酸 、 硫酸 、 硝酸 、 铁粉 、 苯 作用下， 生成 N-(喹啉-5-基)乙酰胺
  参考文献：
  名称：

  Claus; Setzer, Journal fur praktische Chemie (Leipzig 1954), 1896, vol. <2> 53, p. 392

  摘要：

  DOI：

文献信息

• Chemokine receptor binding heterocyclic compounds
  申请人：AnorMED, Inc.

  公开号：US06750348B1

  公开（公告）日：2004-06-15

  This invention relates to a novel class of heterocyclic compounds that bind chemokine receptors, inhibiting the binding of their natural ligands thereby. These compounds result in protective effects against infection by HIV through binding to chemokine receptors, including CXCR4 and CCR5, thus inhibiting the subsequent binding by these chemokines. The present invention provides a compound of Formula I wherein, W is a nitrogen atom and Y is absent or, W is a carbon atom and Y═H; R1 to R7 may be the same or different and are independently selected from hydrogen or straight, branched or cyclic C1-6 alkyl; R8 is a substituted heterocyclic group or a substituted aromatic group Ar is an aromatic or heteroaromatic ring each optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups; n and n′ are independently, 0-2; X is a group of the formula: Wherein, Ring A is an optionally substituted, saturated or unsaturated 5 or 6-membered ring, and P is an optionally substituted carbon atom, an optionally substituted nitrogen atom, sulfur or oxygen atom. Ring B is an optionally substituted 5 to 7-membered ring. Ring A and Ring B in the above formula can be connected to the group W from any position via the group V, wherein V is a chemical bond, a (CH2)n″ group (where n″=0-2) or a C═O group. Z is, (1) a hydrogen atom, (2) an optionally substituted C1-6 alkyl group, (3) a C0-6 alkyl group substituted with an optionally substituted aromatic or heterocyclic group, (4) an optionally substituted C0-6 alkylamino or C3-7 cycloalkylamino group, (5) an optionally substituted carbonyl group or sulfonyl. These compounds further include any pharmaceutically acceptable acid addition salts and metal complexes thereof and any stereoisomeric forms and mixtures of stereoisomeric forms thereof.

  这项发明涉及一类新型的杂环化合物，它们结合趋化因子受体，抑制其天然配体的结合。这些化合物通过结合趋化因子受体，包括CXCR4和CCR5，从而抑制这些趋化因子的后续结合，产生对HIV感染的保护效果。本发明提供了一个式I的化合物 其中，W是氮原子，Y不存在，或者W是碳原子，Y═H； R1至R7可以相同也可以不同，并且独立地选择自氢或直链、支链或环状的C1-6烷基； R8是一个取代的杂环基或取代的芳香基 Ar是一个芳香或杂芳环，每个环在单个或多个非连接位置可选择地取代有电子给体或吸引体基团； n和n′独立地为0-2； X是下式的一个基团： 其中，环A是一个可选择地取代的饱和或不饱和的5或6元环，P是一个可选择地取代的碳原子、一个可选择地取代的氮原子、硫或氧原子。环B是一个可选择地取代的5到7元环。上述式中的环A和环B可以通过基团V从任何位置连接到基团W，其中V是一个化学键，一个(CH2)n″基团（其中n″=0-2）或一个C═O基团。Z是(1)一个氢原子，(2)一个可选择地取代的C1-6烷基基团，(3)一个用可选择地取代的芳香或杂环基团取代的C0-6烷基基团，(4)一个可选择地取代的C0-6烷基氨基或C3-7环烷氨基基团，(5)一个可选择地取代的羰基或磺酰基。这些化合物还包括任何药学上可接受的酸盐和金属络合物，以及它们的任何立体异构体形式和立体异构体形式的混合物。
• Hypervalent Iodine(III)‐Mediated Regioselective Cyanation of Quinoline <i>N</i> ‐Oxides with Trimethylsilyl Cyanide
  作者：Feng Xu、Yuqin Li、Xin Huang、Xinjie Fang、Zhuofei Li、Hongshuo Jiang、Jingyi Qiao、Wenyi Chu、Zhizhong Sun

  DOI：10.1002/adsc.201801185

  日期：2019.2

  A regioselective cyanation of quinoline N‐oxides with trimethylsilyl cyanide was developed by using (Diacetoxyiodo) benzene (PIDA) as mediated hypervalent iodine(III) reagent under metal‐free and base‐free reaction conditions to obtain 2‐cyanoquinolines. The efficient PIDA reagent could play the role of an activator of the substrates and an accelerator of N−O bond cleavage. The reaction system featured

  在无金属和无碱反应条件下，使用（二乙酰氧基碘）苯（PIDA）作为介导的高价碘（III）试剂，开发了用三甲基甲硅烷基氰化喹啉N-氧化物的区域选择性氰化反应，从而获得2-氰基喹啉。高效的PIDA试剂可以起到底物的活化剂和N-O键断裂促进剂的作用。该反应系统具有广泛的底物适用性和高收率的特点。该程序以克级放大以合成结核病（TB）抑制剂。最后，根据一些实验结果，提出了合理的氰化反应机理。
• Direct Synthesis of <i>N</i>-Difluoromethyl-2-pyridones from Pyridines
  作者：Sen Zhou、Xiaoya Hou、Kai Yang、Minjie Guo、Wentao Zhao、Xiangyang Tang、Guangwei Wang

  DOI：10.1021/acs.joc.1c00228

  日期：2021.5.7

  A novel method for the synthesis of N-difluoromethyl-2-pyridones was described. This protocol enables the synthesis of N-difluoromethyl-2-pyridones from readily available pyridines using mild reaction conditions that are compatible with a wide range of functional groups. The preliminary mechanistic study revealed that N-difluoromethylpyridinium salts were the key intermediates to complete this conversion

  描述了一种合成N-二氟甲基-2-吡啶酮的新方法。该方案能够使用温和的反应条件，从易得的吡啶中合成N-二氟甲基-2-吡啶酮，该反应条件与多种官能团相容。初步的机理研究表明，N-二氟甲基吡啶鎓盐是完成该转化的关键中间体。
• [EN] GLYCINE B ANTAGONISTS<br/>[FR] ANTAGONISTES DE LA GLYCINE B
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2010139483A1

  公开（公告）日：2010-12-09

  The invention relates to pyrazolopyrimidine derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.

  该发明涉及吡唑吡咪啉衍生物及其药用可接受的盐。该发明进一步涉及一种制备这种化合物的方法。该发明的化合物是甘氨酸B拮抗剂，因此可用于控制和预防各种疾病，包括神经系统疾病。
• Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
  申请人：——

  公开号：US20030114679A1

  公开（公告）日：2003-06-19

  This invention describes various processes for synthesis and resolution of racemic amino-substituted fused bicyclic ring systems. One process utilizes selective hydrogenation of an amino-substituted fused bicyclic aromatic ring system. An alternative process prepares the racemic amino-substituted fused bicyclic ring system via nitrosation. In addition, the present invention describes the enzymatic resolution of a racemic mixture to produce the (R)- and (S)-forms of amino-substituted fused bicyclic rings as well as a racemization process to recycle the unpreferred enantioner. Further provided by this invention is an asymmetric synthesis of the (R)- or (S)-enantiomer of primary amino-substituted fused bicyclic ring systems.

  该发明描述了合成和分离外消旋氨基取代的融合双环环系统的各种过程。其中一种过程利用选择性氢化氨基取代的融合双环芳香环系统。另一种替代过程通过亚硝化制备外消旋氨基取代的融合双环环系统。此外，该发明描述了酶催化拆分外消旋混合物，以生产氨基取代的融合双环环的(R)-和(S)-形式，以及一个消旋过程来回收未优选的对映体。该发明还提供了外消旋氨基取代的融合双环环系统的(R)-或(S)-对映体的不对称合成。